Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 397

1.

Is there a rationale for the chronic use of phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia?

Roumeguère T, Zouaoui Boudjeltia K, Hauzeur C, Schulman C, Vanhaeverbeek M, Wespes E.

BJU Int. 2009 Aug;104(4):511-7. doi: 10.1111/j.1464-410X.2009.08418.x. Epub 2009 Feb 23. Review.

2.

A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.

Stief CG, Porst H, Neuser D, Beneke M, Ulbrich E.

Eur Urol. 2008 Jun;53(6):1236-44. doi: 10.1016/j.eururo.2008.01.075. Epub 2008 Feb 4.

PMID:
18281145
3.

Phosphodiesterase-5 inhibitors and benign prostatic hyperplasia.

Wang C.

Curr Opin Urol. 2010 Jan;20(1):49-54. doi: 10.1097/MOU.0b013e328333ac68. Review.

PMID:
19887943
4.

Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia.

Gacci M, Eardley I, Giuliano F, Hatzichristou D, Kaplan SA, Maggi M, McVary KT, Mirone V, Porst H, Roehrborn CG.

Eur Urol. 2011 Oct;60(4):809-25. doi: 10.1016/j.eururo.2011.06.037. Epub 2011 Jun 29. Review.

PMID:
21726934
5.

A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.

Gacci M, Corona G, Salvi M, Vignozzi L, McVary KT, Kaplan SA, Roehrborn CG, Serni S, Mirone V, Carini M, Maggi M.

Eur Urol. 2012 May;61(5):994-1003. doi: 10.1016/j.eururo.2012.02.033. Epub 2012 Feb 25. Review.

PMID:
22405510
6.

Phosphodiesterase type 5 inhibitors: the day after.

Hatzimouratidis K, Hatzichristou D.

Eur Urol. 2007 Jan;51(1):75-88; discussion 89. Epub 2006 Aug 1. Review.

PMID:
16949200
7.

PDE5 inhibitors for LUTS.

Mouli S, McVary KT.

Prostate Cancer Prostatic Dis. 2009;12(4):316-24. doi: 10.1038/pcan.2009.27. Epub 2009 Aug 18. Review.

PMID:
19687801
8.

Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia in men with or without erectile dysfunction.

Broderick GA, Brock GB, Roehrborn CG, Watts SD, Elion-Mboussa A, Viktrup L.

Urology. 2010 Jun;75(6):1452-8. doi: 10.1016/j.urology.2009.09.093. Epub 2010 Feb 16.

PMID:
20163842
9.

Role of phosphodiesterase type 5 inhibitors for lower urinary tract symptoms.

Miller MS.

Ann Pharmacother. 2013 Feb;47(2):278-83. doi: 10.1345/aph.1R528. Epub 2013 Feb 5. Review.

PMID:
23386068
10.

Sildenafil citrate improves erectile function: a randomised double-blind trial with open-label extension.

McVary KT, Kaufman J, Young JM, Tseng LJ.

Int J Clin Pract. 2007 Nov;61(11):1843-9. Epub 2007 Sep 20.

PMID:
17887993
11.
12.

Phosphodiesterase-5 inhibitors in the treatment of lower urinary tract symptoms and benign prostatic hyperplasia.

Giannitsas K, Mitropoulos D, Konstantinopoulos A, Athanasopoulos A, Perimenis P.

Expert Opin Pharmacother. 2008 Jul;9(10):1687-93. doi: 10.1517/14656566.9.10.1687 . Review.

PMID:
18570602
13.

Activity of phosphodiesterase type 5 inhibitors in patients with lower urinary tract symptoms due to benign prostatic hyperplasia.

Zhao C, Kim SH, Lee SW, Jeon JH, Kang KK, Choi SB, Park JK.

BJU Int. 2011 Jun;107(12):1943-7. doi: 10.1111/j.1464-410X.2010.09759.x. Epub 2010 Nov 5.

14.

Tadalafil for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.

Gonzalez RR, Kaplan SA.

Expert Opin Drug Metab Toxicol. 2006 Aug;2(4):609-17. Review.

PMID:
16859408
15.

Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia.

McVary KT, Roehrborn CG, Kaminetsky JC, Auerbach SM, Wachs B, Young JM, Esler A, Sides GD, Denes BS.

J Urol. 2007 Apr;177(4):1401-7.

PMID:
17382741
16.

Acceptance of and discontinuation rate from erectile dysfunction oral treatment in patients following bilateral nerve-sparing radical prostatectomy.

Salonia A, Gallina A, Zanni G, Briganti A, Dehò F, Saccà A, Suardi N, Barbieri L, Guazzoni G, Rigatti P, Montorsi F.

Eur Urol. 2008 Mar;53(3):564-70. Epub 2007 Aug 20.

PMID:
17761385
17.

Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study.

Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L.

J Urol. 2008 Oct;180(4):1228-34. doi: 10.1016/j.juro.2008.06.079. Epub 2008 Aug 22.

PMID:
18722631
18.

Mechanism of Phosphodiesterase 5 inhibitor relief of prostatitis symptoms.

Grimsley SJ, Khan MH, Jones GE.

Med Hypotheses. 2007;69(1):25-6. Epub 2007 Feb 14.

PMID:
17300876
19.

Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia.

Porst H, McVary KT, Montorsi F, Sutherland P, Elion-Mboussa A, Wolka AM, Viktrup L.

Eur Urol. 2009 Oct;56(4):727-35. doi: 10.1016/j.eururo.2009.04.033. Epub 2009 Apr 22. Erratum in: Eur Urol. 2011 Jun;59(6):1082.

PMID:
19409693

Supplemental Content

Support Center